{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:54:56Z","timestamp":1794030896435,"version":"4.8.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41582-024-01050-x","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T12:56:21Z","timestamp":1736945781000},"page":"140-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder \u2014 recommendations from ECTRIMS and the EBMT"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3822-1218","authenticated-orcid":false,"given":"Paolo A.","family":"Muraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-7067","authenticated-orcid":false,"given":"Alice","family":"Mariottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-1806","authenticated-orcid":false,"given":"Joachim","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Iacobaeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6819-3476","authenticated-orcid":false,"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-0097","authenticated-orcid":false,"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-3760","authenticated-orcid":false,"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8675-4433","authenticated-orcid":false,"given":"Lars","family":"B\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":false,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-9772","authenticated-orcid":false,"given":"Jeffrey A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8656-4250","authenticated-orcid":false,"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-6297","authenticated-orcid":false,"given":"Majid","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-284X","authenticated-orcid":false,"given":"Kirill","family":"Kirzigov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Mancardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-5359","authenticated-orcid":false,"given":"Mar","family":"Tintor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"Sharrack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Attendees of the ECTRIMS Focused Workshop on HSCT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Izmail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iljias","family":"Jelcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kristine","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Mycko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Zephir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"1050_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1126\/science.adg7489","volume":"380","author":"PA Muraro","year":"2023","unstructured":"Muraro, P. A. Resetting tolerance in autoimmune disease. Science 380, 470\u2013471 (2023).","journal-title":"Science"},{"key":"1050_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden, J. A. et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 57, 1217\u20131239 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B. & Ciccarelli, O. Multiple sclerosis. Lancet 391, 1622\u20131636 (2018).","journal-title":"Lancet"},{"key":"1050_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177\u2013189 (2015).","journal-title":"Neurology"},{"key":"1050_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","volume":"13","author":"PA Muraro","year":"2017","unstructured":"Muraro, P. A. et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat. Rev. Neurol. 13, 391\u2013405 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1050_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2020-061514","author":"B Sharrack","year":"2022","unstructured":"Sharrack, B., Petrie, J., Coles, A. & Snowden, J. A. Is stem cell transplantation safe and effective in multiple sclerosis. BMJ https:\/\/doi.org\/10.1136\/bmj-2020-061514 (2022).","journal-title":"BMJ"},{"key":"1050_CR7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","volume":"88","author":"MP Sormani","year":"2017","unstructured":"Sormani, M. P. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Neurology 88, 2115\u20132122 (2017).","journal-title":"Neurology"},{"key":"1050_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjh.18176","volume":"198","author":"FR Achini-Gutzwiller","year":"2022","unstructured":"Achini-Gutzwiller, F. R. et al. Haematopoietic stem cell transplantation for severe autoimmune diseases in children: a review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. Br. J. Haematol. 198, 24\u201345 (2022).","journal-title":"Br. J. Haematol."},{"key":"1050_CR9","unstructured":"European Committee for Treatment and Research in Multiple Sclerosis. 9th ECTRIMS Focused Workshop: Autologous Haematopoietic Stem Cell Transplantation for Treatment of MS and Related Diseases. ECTRIMS ectrims.eu\/ongoing-educational-programmes\/focused-workshops\/ (2022)."},{"key":"1050_CR10","unstructured":"European Committee for Treatment and Research in Multiple Sclerosis. 9th ECTRIMS Focused Workshop: Autologous Haematopoietic Stem Cell Transplantation for Treatment of MS and Related Diseases. ECTRIMS https:\/\/ectrims.conference2web.com\/filter?event_groups=Focused+Workshop&starts_at_years=2022 (2022)."},{"key":"1050_CR11","unstructured":"European Committee for Treatment and Research in Multiple Sclerosis. Highlights from the 9th ECTRIMS Focused Workshop, 2022. ECTRIMS https:\/\/ectrims.eu\/app\/uploads\/2022\/03\/9th-ECTRIMS-Focused-Workshop-2022.pdf (2022)."},{"key":"1050_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic, I. et al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell 175, 85\u2013100.e23 (2018).","journal-title":"Cell"},{"key":"1050_CR13","doi-asserted-by":"publisher","first-page":"813957","DOI":"10.3389\/fimmu.2021.813957","volume":"12","author":"MT Cencioni","year":"2021","unstructured":"Cencioni, M. T. et al. Immune reconstitution following autologous hematopoietic stem cell transplantation for multiple sclerosis: a review on behalf of the EBMT Autoimmune Diseases Working Party. Front. Immunol. 12, 813957 (2021).","journal-title":"Front. Immunol."},{"key":"1050_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","volume":"72","author":"RA Nash","year":"2015","unstructured":"Nash, R. A. et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 72, 159\u2013169 (2015).","journal-title":"JAMA Neurol."},{"key":"1050_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ana.23784","volume":"73","author":"PJ Darlington","year":"2013","unstructured":"Darlington, P. J. et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann. Neurol. 73, 341\u2013354 (2013).","journal-title":"Ann. Neurol."},{"key":"1050_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/jnnp-2018-319446","volume":"90","author":"JJ Moore","year":"2019","unstructured":"Moore, J. J. et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 514\u2013521 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR17","doi-asserted-by":"publisher","first-page":"eabq1693","DOI":"10.1126\/scitranslmed.abq1693","volume":"14","author":"J Ruder","year":"2022","unstructured":"Ruder, J. et al. Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis. Sci. Transl. Med. 14, eabq1693 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1050_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1084\/jem.20041679","volume":"201","author":"PA Muraro","year":"2005","unstructured":"Muraro, P. A. et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 201, 805\u2013816 (2005).","journal-title":"J. Exp. Med."},{"key":"1050_CR19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1172\/JCI71691","volume":"124","author":"PA Muraro","year":"2014","unstructured":"Muraro, P. A. et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J. Clin. Invest. 124, 1168\u20131172 (2014).","journal-title":"J. Clin. Invest."},{"key":"1050_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127655","volume":"5","author":"KM Harris","year":"2020","unstructured":"Harris, K. M. et al. Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis. JCI Insight 5, e127655 (2020).","journal-title":"JCI Insight"},{"key":"1050_CR21","doi-asserted-by":"publisher","first-page":"103429","DOI":"10.1016\/j.ebiom.2021.103429","volume":"68","author":"R Amoriello","year":"2021","unstructured":"Amoriello, R. et al. TCR repertoire diversity in multiple sclerosis: high-dimensional bioinformatics analysis of sequences from brain, cerebrospinal fluid and peripheral blood. EBioMedicine 68, 103429 (2021).","journal-title":"EBioMedicine"},{"key":"1050_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3389\/fimmu.2018.00834","volume":"9","author":"PJ Darlington","year":"2018","unstructured":"Darlington, P. J. et al. Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis. Front. Immunol. 9, 834 (2018).","journal-title":"Front. Immunol."},{"key":"1050_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/bmt.2014.277","volume":"50","author":"LC Arruda","year":"2015","unstructured":"Arruda, L. C. et al. Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients. Bone Marrow Transpl. 50, 380\u2013389 (2015).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/cei.12895","volume":"187","author":"G de Oliveira","year":"2017","unstructured":"de Oliveira, G. et al. Defective expression of apoptosis\u2010related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation. Clin. Exp. Immunol. 187, 383\u2013398 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"1050_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1042\/CS20140095","volume":"128","author":"A de Paula A Sousa","year":"2015","unstructured":"de Paula A Sousa, A. et al. Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis. Clin. Sci. 128, 111\u2013120 (2015).","journal-title":"Clin. Sci."},{"key":"1050_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200027","volume":"9","author":"V von Niederh\u00e4usern","year":"2022","unstructured":"von Niederh\u00e4usern, V. et al. B-cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 9, e200027 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1050_CR27","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1093\/brain\/awt182","volume":"136","author":"SV Abrahamsson","year":"2013","unstructured":"Abrahamsson, S. V. et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136, 2888\u20132903 (2013).","journal-title":"Brain"},{"key":"1050_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/acn3.51510","volume":"9","author":"M Visweswaran","year":"2022","unstructured":"Visweswaran, M. et al. Sustained immunotolerance in multupe sclerosis after stem cell transplant. Ann. Clin. Transl. Neurol. 9, 206\u2013220 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1050_CR29","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.3389\/fimmu.2021.794077","volume":"12","author":"J Ruder","year":"2021","unstructured":"Ruder, J. et al. NK cells and innate-like T cells after autologous hematopoietic stem cell transplantation in multiple sclerosis. Front. Immunol. 12, 5398 (2021).","journal-title":"Front. Immunol."},{"key":"1050_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbmt.2007.03.001","volume":"13","author":"B Van Wijmeersch","year":"2007","unstructured":"Van Wijmeersch, B. et al. Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect. Biol. Blood Marrow Transpl. 13, 627\u2013637 (2007).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1050_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"B Sharrack","year":"2020","unstructured":"Sharrack, B. et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transpl. 55, 283\u2013306 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/cei.12985","volume":"189","author":"FG Karnell","year":"2017","unstructured":"Karnell, F. G. et al. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. Clin. Exp. Immunol. 189, 268\u2013278 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"1050_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14118-w","volume":"11","author":"D Schafflick","year":"2020","unstructured":"Schafflick, D. et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat. Commun. 11, 247 (2020).","journal-title":"Nat. Commun."},{"key":"1050_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/bmt.2014.251","volume":"50","author":"T Alexander","year":"2015","unstructured":"Alexander, T. et al. SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transpl. 50, 173\u2013180 (2015).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR35","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1007\/s00415-022-11063-5","volume":"269","author":"AG Willison","year":"2022","unstructured":"Willison, A. G., Ruck, T., Lenz, G., Hartung, H. P. & Meuth, S. G. The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. J. Neurol. 269, 3937\u20133958 (2022).","journal-title":"J. Neurol."},{"key":"1050_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","volume":"20","author":"A Fassas","year":"1997","unstructured":"Fassas, A. et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transpl. 20, 631\u2013638 (1997).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/sj.bmt.1701129","volume":"21","author":"R Burt","year":"1998","unstructured":"Burt, R. et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone marrow Transplant. 21, 537\u2013541 (1998).","journal-title":"Bone marrow Transplant."},{"key":"1050_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ane.13147","volume":"140","author":"A Tolf","year":"2019","unstructured":"Tolf, A. et al. Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation. Acta Neurol. Scand. 140, 320\u2013327 (2019).","journal-title":"Acta Neurol. Scand."},{"key":"1050_CR39","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1177\/1352458519893926","volume":"26","author":"SAS Kvistad","year":"2019","unstructured":"Kvistad, S. A. S. et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Mult. Scler. 26, 1889\u20131897 (2019).","journal-title":"Mult. Scler."},{"key":"1050_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1352458520902392","volume":"27","author":"A Mariottini","year":"2021","unstructured":"Mariottini, A. et al. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. Mult. Scler. 27, 61\u201370 (2021).","journal-title":"Mult. Scler."},{"key":"1050_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78160-1","volume":"10","author":"N Giedraitiene","year":"2020","unstructured":"Giedraitiene, N., Kizlaitiene, R., Peceliunas, V., Griskevicius, L. & Kaubrys, G. Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis. Sci. Rep. 10, 21286 (2020).","journal-title":"Sci. Rep."},{"key":"1050_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4103\/0028-3886.284385","volume":"68","author":"A Dayama","year":"2020","unstructured":"Dayama, A., Bhargava, R., Kurmi, S. R., Jain, S. & Dua, V. Autologous stem cell transplant in adult multiple sclerosis patients: a study from North India. Neurol. India 68, 454\u2013457 (2020).","journal-title":"Neurol. India"},{"key":"1050_CR43","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1177\/1352458520985238","volume":"27","author":"J Das","year":"2021","unstructured":"Das, J. et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with \u2018aggressive\u2019 multiple sclerosis. Mult. Scler. J. 27, 1198\u20131204 (2021).","journal-title":"Mult. Scler. J."},{"key":"1050_CR44","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1212\/WNL.0000000000012449","volume":"97","author":"RS Nicholas","year":"2021","unstructured":"Nicholas, R. S. et al. Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series. Neurology 97, e890\u2013e901 (2021).","journal-title":"Neurology"},{"key":"1050_CR45","doi-asserted-by":"publisher","first-page":"e1215","DOI":"10.1212\/WNL.0000000000011461","volume":"96","author":"G Boffa","year":"2021","unstructured":"Boffa, G. et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology 96, e1215\u2013e1226 (2021).","journal-title":"Neurology"},{"key":"1050_CR46","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00415-021-10820-2","volume":"269","author":"RK Burt","year":"2022","unstructured":"Burt, R. K., Han, X., Quigley, K., Helenowski, I. B. & Balabanov, R. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. J. Neurol. 269, 2513\u20132526 (2022).","journal-title":"J. Neurol."},{"key":"1050_CR47","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/jnnp-2022-328797","volume":"93","author":"SAS Kvistad","year":"2022","unstructured":"Kvistad, S. A. S. et al. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. J. Neurol. Neurosurg. Psychiatry 93, 844\u2013848 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR48","doi-asserted-by":"publisher","first-page":"820256","DOI":"10.3389\/fneur.2022.820256","volume":"13","author":"A Mariottini","year":"2022","unstructured":"Mariottini, A. et al. Intermediate-intensity autologous hematopoietic stem cell transplantation reduces serum neurofilament light chains and brain atrophy in aggressive multiple sclerosis. Front. Neurol. 13, 820256 (2022).","journal-title":"Front. Neurol."},{"key":"1050_CR49","doi-asserted-by":"publisher","first-page":"10946","DOI":"10.3390\/ijms231810946","volume":"23","author":"J Ruder","year":"2022","unstructured":"Ruder, J. et al. Dynamics of inflammatory and neurodegenerative biomarkers after autologous hematopoietic stem cell transplantation in multiple sclerosis. Int. J. Mol. Sci. 23, 10946 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1050_CR50","doi-asserted-by":"publisher","first-page":"104210","DOI":"10.1016\/j.msard.2022.104210","volume":"68","author":"C Zjukovskaja","year":"2022","unstructured":"Zjukovskaja, C., Larsson, A., Cherif, H., Kultima, K. & Burman, J. Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis. Mult. Scler. Relat. Disord. 68, 104210 (2022).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/jnnp-2023-331864","volume":"95","author":"T Silfverberg","year":"2023","unstructured":"Silfverberg, T. et al. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study. J. Neurol. Neurosurg. Psychiatry 95, 125\u2013133 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR52","doi-asserted-by":"publisher","first-page":"104829","DOI":"10.1016\/j.msard.2023.104829","volume":"76","author":"F Jespersen","year":"2023","unstructured":"Jespersen, F. et al. Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience. Mult. Scler. Relat. Disord. 76, 104829 (2023).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/13524585241231665","volume":"30","author":"CE Kvistad","year":"2024","unstructured":"Kvistad, C. E. et al. Autologous hematopoietic stem cell transplantation for multiple sclerosis: long-term follow-up data from Norway. Mult. Scler. 30, 751\u2013754 (2024).","journal-title":"Mult. Scler."},{"key":"1050_CR54","first-page":"e1215","volume":"22","author":"G Boffa","year":"2022","unstructured":"Boffa, G. et al. Hematopoietic stem cell transplantation in people with active secondary progressive multiple sclerosis. Neurology 22, e1215\u2013e1226 (2022).","journal-title":"Neurology"},{"key":"1050_CR55","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jnnp-2020-323992","volume":"92","author":"C Zhukovsky","year":"2021","unstructured":"Zhukovsky, C. et al. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing\u2013remitting multiple sclerosis: an observational study. J. Neurol. Neurosurg. Psychiatry 92, 189\u2013194 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR56","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/ene.14324","volume":"27","author":"G Boffa","year":"2020","unstructured":"Boffa, G. et al. Aggressive multiple sclerosis: a single\u2010centre, real\u2010world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. Eur. J. Neurol. 27, 2047\u20132055 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1050_CR57","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/acn3.51366","volume":"8","author":"V H\u00e4u\u00dfler","year":"2021","unstructured":"H\u00e4u\u00dfler, V. et al. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis. Ann. Clin. Transl. Neurol. 8, 1269\u20131278 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1050_CR58","doi-asserted-by":"publisher","first-page":"105096","DOI":"10.1016\/j.msard.2023.105096","volume":"80","author":"M Vaisvilas","year":"2023","unstructured":"Vaisvilas, M., Kaubrys, G., Kizlaitiene, R., Taluntiene, V. & Giedraitiene, N. Autologous hematopoietic stem cell transplantation is superior to alemtuzumab in patients with highly active relapsing multiple sclerosis and severe disability. Mult. Scler. Relat. Disord. 80, 105096 (2023).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR59","doi-asserted-by":"publisher","first-page":"105414","DOI":"10.1016\/j.msard.2023.105414","volume":"82","author":"B Braun","year":"2023","unstructured":"Braun, B. et al. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: sustained improvement in cognition and quality of life. Mult. Scler. Relat. Disord. 82, 105414 (2023).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR60","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/ene.15280","volume":"29","author":"A Mariottini","year":"2022","unstructured":"Mariottini, A. et al. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis. Eur. J. Neurol. 29, 1708\u20131718 (2022).","journal-title":"Eur. J. Neurol."},{"key":"1050_CR61","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/jnnp-2023-332790","volume":"95","author":"T Kalincik","year":"2024","unstructured":"Kalincik, T. et al. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 95, 775\u2013783 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR62","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","volume":"80","author":"T Kalincik","year":"2023","unstructured":"Kalincik, T. et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol. 80, 702\u2013713 (2023).","journal-title":"JAMA Neurol."},{"key":"1050_CR63","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2014.17986","volume":"313","author":"RK Burt","year":"2015","unstructured":"Burt, R. K. et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA 313, 275\u2013284 (2015).","journal-title":"JAMA"},{"key":"1050_CR64","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","volume":"88","author":"RA Nash","year":"2017","unstructured":"Nash, R. A. et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology 88, 842\u2013852 (2017).","journal-title":"Neurology"},{"key":"1050_CR65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","volume":"74","author":"PA Muraro","year":"2017","unstructured":"Muraro, P. A. et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 74, 459\u2013469 (2017).","journal-title":"JAMA Neurol."},{"key":"1050_CR66","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor, R. et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 17, 405\u2013415 (2018).","journal-title":"Lancet Neurol."},{"key":"1050_CR67","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2003-03-0877","volume":"102","author":"RK Burt","year":"2003","unstructured":"Burt, R. K. et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102, 2373\u20132378 (2003).","journal-title":"Blood"},{"key":"1050_CR68","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/1352458510364538","volume":"16","author":"E Krasulov\u00e1","year":"2010","unstructured":"Krasulov\u00e1, E. et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult. Scler. J. 16, 685\u2013693 (2010).","journal-title":"Mult. Scler. J."},{"key":"1050_CR69","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10072-011-0859-y","volume":"33","author":"B Chen","year":"2012","unstructured":"Chen, B. et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol. Sci. 33, 881\u2013886 (2012).","journal-title":"Neurol. Sci."},{"key":"1050_CR70","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1212\/WNL.0b013e318211c537","volume":"76","author":"A Fassas","year":"2011","unstructured":"Fassas, A. et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76, 1066\u20131070 (2011).","journal-title":"Neurology"},{"key":"1050_CR71","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/bmt.2011.208","volume":"47","author":"JD Bowen","year":"2012","unstructured":"Bowen, J. D. et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 47, 946\u2013951 (2012).","journal-title":"Bone Marrow Transplant."},{"key":"1050_CR72","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1177\/1352458511429320","volume":"18","author":"G Mancardi","year":"2012","unstructured":"Mancardi, G. et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult. Scler. J. 18, 835\u2013842 (2012).","journal-title":"Mult. Scler. J."},{"key":"1050_CR73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/jnnp.2005.063883","volume":"77","author":"JP Samijn","year":"2006","unstructured":"Samijn, J. P. et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 77, 46\u201350 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR74","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1097\/00029330-200611020-00001","volume":"119","author":"J Xu","year":"2006","unstructured":"Xu, J. et al. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin. Med. J. 119, 1851\u20131855 (2006).","journal-title":"Chin. Med. J."},{"key":"1050_CR75","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/nm749","volume":"8","author":"ML Monje","year":"2002","unstructured":"Monje, M. L., Mizumatsu, S., Fike, J. R. & Palmer, T. D. Irradiation induces neural precursor-cell dysfunction. Nat. Med. 8, 955\u2013962 (2002).","journal-title":"Nat. Med."},{"key":"1050_CR76","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1212\/WNL.43.10.2105","volume":"43","author":"K Peterson","year":"1993","unstructured":"Peterson, K. et al. Effect of brain irradiation on demyelinating lesions. Neurology 43, 2105\u20132105 (1993).","journal-title":"Neurology"},{"key":"1050_CR77","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ana.410220513","volume":"22","author":"SD Cook","year":"1987","unstructured":"Cook, S. D. et al. Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann. Neurol. 22, 634\u2013638 (1987).","journal-title":"Ann. Neurol."},{"key":"1050_CR78","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458516650992","volume":"23","author":"H Lee","year":"2017","unstructured":"Lee, H. et al. Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. Mult. Scler. 23, 420\u2013431 (2017).","journal-title":"Mult. Scler."},{"key":"1050_CR79","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000598","volume":"6","author":"S Thebault","year":"2019","unstructured":"Thebault, S. et al. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurol. Neuroimmunol. Neuroinflamm 6, e598 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"1050_CR80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1023\/A:1006686426090","volume":"20","author":"A Fassas","year":"2000","unstructured":"Fassas, A. et al. Autologous stem cell transplantation in progressive multiple sclerosis \u2013 an interim analysis of efficacy. J. Clin. Immunol. 20, 24\u201330 (2000).","journal-title":"J. Clin. Immunol."},{"key":"1050_CR81","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","volume":"84","author":"GL Mancardi","year":"2015","unstructured":"Mancardi, G. L. et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 84, 981\u2013988 (2015).","journal-title":"Neurology"},{"key":"1050_CR82","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","volume":"321","author":"RK Burt","year":"2019","unstructured":"Burt, R. K. et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA 321, 165\u2013174 (2019).","journal-title":"JAMA"},{"key":"1050_CR83","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1352458516645670","volume":"23","author":"MP Sormani","year":"2017","unstructured":"Sormani, M. P., Muraro, P. A., Saccardi, R. & Mancardi, G. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. Mult. Scler. 23, 201\u2013204 (2017).","journal-title":"Mult. Scler."},{"key":"1050_CR84","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40120-022-00389-x","volume":"11","author":"F Nabizadeh","year":"2022","unstructured":"Nabizadeh, F. et al. Autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. Neurol. Ther. 11, 1553\u20131569 (2022).","journal-title":"Neurol. Ther."},{"key":"1050_CR85","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood-2004-08-3205","volume":"105","author":"R Saccardi","year":"2005","unstructured":"Saccardi, R. et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105, 2601\u20132607 (2005).","journal-title":"Blood"},{"key":"1050_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19748-7","volume":"12","author":"N Giedraitiene","year":"2022","unstructured":"Giedraitiene, N., Gasciauskaite, G. & Kaubrys, G. Impact of autologous HSCT on the quality of life and fatigue in patients with relapsing multiple sclerosis. Sci. Rep. 12, 15404 (2022).","journal-title":"Sci. Rep."},{"key":"1050_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297573","volume":"19","author":"A Tolf","year":"2024","unstructured":"Tolf, A., Gauffin, H., Burman, J., Landtblom, A. M. & Flensner, G. Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a qualitative interview study. PLoS ONE 19, e0297573 (2024).","journal-title":"PLoS ONE"},{"key":"1050_CR88","doi-asserted-by":"publisher","first-page":"1384551","DOI":"10.3389\/fneur.2024.1384551","volume":"15","author":"T Volz","year":"2024","unstructured":"Volz, T. et al. \u201cA second birthday\u201d? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation \u2013 a qualitative interview study. Front. Neurol. 15, 1384551 (2024).","journal-title":"Front. Neurol."},{"key":"1050_CR89","doi-asserted-by":"publisher","first-page":"101467","DOI":"10.1016\/j.msard.2019.101467","volume":"37","author":"F De Kleermaeker","year":"2020","unstructured":"De Kleermaeker, F., Uitdehaag, B. M. J. & van Oosten, B. W. Patients\u2019 expectations of autologous hematopoietic stem cell transplantation as a treatment for MS. Mult. Scler. Relat. Disord. 37, 101467 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR90","first-page":"100283","volume":"3","author":"T Alexander","year":"2024","unstructured":"Alexander, T. et al. Patient-reported-outcomes in HSCT for autoimmune diseases: considerations on behalf of the EBMT ADWP, PAC and Nurses Group. J. Allergy Clin. Immunol.: Glob. 3, 100283 (2024).","journal-title":"J. Allergy Clin. Immunol.: Glob."},{"key":"1050_CR91","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes, M. P. et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 20, 653\u2013670 (2021).","journal-title":"Lancet Neurol."},{"key":"1050_CR92","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2019.02.014","volume":"25","author":"JA Cohen","year":"2019","unstructured":"Cohen, J. A. et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation. Biol. Blood Marrow Transpl. 25, 845\u2013854 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1050_CR93","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","volume":"78","author":"AE Miller","year":"2021","unstructured":"Miller, A. E. et al. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society. JAMA Neurol. 78, 241\u2013246 (2021).","journal-title":"JAMA Neurol."},{"key":"1050_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.htct.2020.03.002","volume":"43","author":"MC Oliveira","year":"2021","unstructured":"Oliveira, M. C. et al. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn\u2019s disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematol. Transfus. Cell Ther. 43, 65\u201386 (2021).","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"1050_CR95","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban, X. et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur. J. Neurol. 25, 215\u2013237 (2018).","journal-title":"Eur. J. Neurol."},{"key":"1050_CR96","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0016","volume":"12","author":"IA Samjoo","year":"2023","unstructured":"Samjoo, I. A. et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J. Comp. Eff. Res. 12, e230016 (2023).","journal-title":"J. Comp. Eff. Res."},{"key":"1050_CR97","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo, I. A. et al. Efficacy classification of modern therapies in multiple sclerosis. J. Comp. Eff. Res. 10, 495\u2013507 (2021).","journal-title":"J. Comp. Eff. Res."},{"key":"1050_CR98","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown, J. W. L. et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321, 175\u2013187 (2019).","journal-title":"JAMA"},{"key":"1050_CR99","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding, K. et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 76, 536\u2013541 (2019).","journal-title":"JAMA Neurol."},{"key":"1050_CR100","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","volume":"95","author":"MD Buron","year":"2020","unstructured":"Buron, M. D. et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology 95, e1041\u2013e1051 (2020).","journal-title":"Neurology"},{"key":"1050_CR101","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He, A. et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19, 307\u2013316 (2020).","journal-title":"Lancet Neurol."},{"key":"1050_CR102","doi-asserted-by":"publisher","first-page":"175628642110195","DOI":"10.1177\/17562864211019574","volume":"14","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano, P. et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther. Adv. Neurol. Disord. 14, 17562864211019574 (2021).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"1050_CR103","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrneurol.2015.85","volume":"11","author":"CA Rush","year":"2015","unstructured":"Rush, C. A., MacLean, H. J. & Freedman, M. S. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat. Rev. Neurol. 11, 379\u2013389 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"1050_CR104","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1352458520925369","volume":"26","author":"E Iacobaeus","year":"2020","unstructured":"Iacobaeus, E. et al. Aggressive multiple sclerosis (1): towards a definition of the phenotype. Mult. Scler. J. 26, 1031\u20131044 (2020).","journal-title":"Mult. Scler. J."},{"key":"1050_CR105","unstructured":"US National Library of Medicine. ClinicalTrials.gov clinicaltrials.gov\/ct2\/show\/study\/NCT03477500?term=NCT03477500&cond=Multiple+Sclerosis&draw=2&rank=1 (2024)."},{"key":"1050_CR106","unstructured":"European Medicines Agency. EudraCT www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001549-42\/GB (2019)."},{"key":"1050_CR107","unstructured":"US National Library of Medicine. ClinicalTrials.gov clinicaltrials.gov\/ct2\/show\/NCT04047628?term=NCT04047628&draw=2&rank=1 (2024)."},{"key":"1050_CR108","unstructured":"European Medicines Agency. EudraCT www.clinicaltrialsregister.eu\/ctr-search\/trial\/2022-002654-95\/IT (2023)."},{"key":"1050_CR109","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel, T. et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J. Neurol. 271, 141\u2013176 (2024).","journal-title":"J. Neurol."},{"key":"1050_CR110","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jocn.2022.08.020","volume":"105","author":"F Nabizadeh","year":"2022","unstructured":"Nabizadeh, F. et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. J. Clin. Neurosci. 105, 37\u201344 (2022).","journal-title":"J. Clin. Neurosci."},{"key":"1050_CR111","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1352458514541978","volume":"21","author":"R Greco","year":"2015","unstructured":"Greco, R. et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party. Mult. Scler. 21, 189\u2013197 (2015).","journal-title":"Mult. Scler."},{"key":"1050_CR112","doi-asserted-by":"publisher","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","volume":"93","author":"RK Burt","year":"2019","unstructured":"Burt, R. K. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology 93, e1732\u2013e1741 (2019).","journal-title":"Neurology"},{"key":"1050_CR113","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3389\/fimmu.2019.01570","volume":"10","author":"R Greco","year":"2019","unstructured":"Greco, R. et al. Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP working parties. Front. Immunol. 10, 1570 (2019).","journal-title":"Front. Immunol."},{"key":"1050_CR114","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/ana.24079","volume":"75","author":"R Greco","year":"2014","unstructured":"Greco, R. et al. Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Ann. Neurol. 75, 447\u2013453 (2014).","journal-title":"Ann. Neurol."},{"key":"1050_CR115","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","volume":"1","author":"JA Snowden","year":"2017","unstructured":"Snowden, J. A. et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. Blood Adv. 1, 2742\u20132755 (2017).","journal-title":"Blood Adv."},{"key":"1050_CR116","doi-asserted-by":"publisher","first-page":"102404","DOI":"10.1016\/j.msard.2020.102404","volume":"45","author":"RK Burt","year":"2020","unstructured":"Burt, R. K. et al. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Mult. Scler. Relat. Disord. 45, 102404 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR117","doi-asserted-by":"crossref","unstructured":"Hughes, S. L., Prettyjohns, M. J., Snowden, J. A. & Sharrack, B. in Handbook of Clinical Neurology, Vol. 202 (eds Inglese, M. & Mancardi, G. L.) Ch. 18, 279\u2013294 (Elsevier, 2024).","DOI":"10.1016\/B978-0-323-90242-7.00007-9"},{"key":"1050_CR118","doi-asserted-by":"publisher","first-page":"105507","DOI":"10.1016\/j.msard.2024.105507","volume":"84","author":"KN Gottschlich","year":"2024","unstructured":"Gottschlich, K. N. et al. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis. Mult. Scler. Relat. Disord. 84, 105507 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR119","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1016\/j.eclinm.2024.102476","volume":"69","author":"R Greco","year":"2024","unstructured":"Greco, R. et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine 69, 102476 (2024).","journal-title":"eClinicalMedicine"},{"key":"1050_CR120","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2014.248","volume":"50","author":"E Snarski","year":"2015","unstructured":"Snarski, E. et al. Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party (ADWP). Bone Marrow Transpl. 50, 216\u2013220 (2015).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR121","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1177\/13524585211000616","volume":"27","author":"C Massarotti","year":"2021","unstructured":"Massarotti, C. et al. Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis. Mult. Scler. 27, 2103\u20132107 (2021).","journal-title":"Mult. Scler."},{"key":"1050_CR122","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1177\/13524585211005660","volume":"27","author":"S Chatterton","year":"2021","unstructured":"Chatterton, S. et al. Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis. Mult. Scler. 27, 2112\u20132115 (2021).","journal-title":"Mult. Scler."},{"key":"1050_CR123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0284288","volume":"18","author":"L Zafeiri","year":"2023","unstructured":"Zafeiri, L. et al. Anti-M\u00fcllerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis. PLoS ONE 18, e0284288 (2023).","journal-title":"PLoS ONE"},{"key":"1050_CR124","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/j.bbmt.2019.07.038","volume":"25","author":"J Murphy","year":"2019","unstructured":"Murphy, J., McKenna, M., Abdelazim, S., Battiwalla, M. & Stratton, P. A practical guide to gynecologic and reproductive health in women undergoing hematopoietic stem cell transplant. Biol. Blood Marrow Transpl. 25, e331\u2013e343 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1050_CR125","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00296-016-3531-2","volume":"36","author":"G Massenkeil","year":"2016","unstructured":"Massenkeil, G. et al. Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation. Rheumatol. Int. 36, 1563\u20131568 (2016).","journal-title":"Rheumatol. Int."},{"key":"1050_CR126","doi-asserted-by":"publisher","first-page":"101369","DOI":"10.1016\/j.beem.2019.101369","volume":"33","author":"J Khizroeva","year":"2019","unstructured":"Khizroeva, J. et al. Infertility in women with systemic autoimmune diseases. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101369 (2019).","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"1050_CR127","first-page":"CD008018","volume":"3","author":"H Chen","year":"2019","unstructured":"Chen, H., Xiao, L., Li, J., Cui, L. & Huang, W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst. Rev. 3, CD008018 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1050_CR128","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s41409-022-01591-z","volume":"57","author":"R Phelan","year":"2022","unstructured":"Phelan, R. et al. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transpl. 57, 1150\u20131163 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR129","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.1212\/WNL.0000000000011545","volume":"96","author":"P Alping","year":"2021","unstructured":"Alping, P., Burman, J., Lycke, J., Frisell, T. & Piehl, F. Safety of alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis. Neurology 96, e1574\u2013e1584 (2021).","journal-title":"Neurology"},{"key":"1050_CR130","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","volume":"388","author":"HL Atkins","year":"2016","unstructured":"Atkins, H. L. et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388, 576\u2013585 (2016).","journal-title":"Lancet"},{"key":"1050_CR131","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1177\/1352458514564484","volume":"21","author":"D Curro","year":"2015","unstructured":"Curro, D. et al. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study. Mult. Scler. 21, 1423\u20131430 (2015).","journal-title":"Mult. Scler."},{"issue":"Suppl. 1","key":"1050_CR132","first-page":"41","volume":"59","author":"R Saccardi","year":"2024","unstructured":"Saccardi, R. et al. BEAM\/ATG or cyclophosphamide\/ATG as conditioning regimen in autologous transplantation for multiple sclerosis: a retrospective analysis of the EBMT Autoimmune Diseases Working Party [abstract O036]. Bone Marrow Transpl. 59 (Suppl. 1), 41 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR133","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/bmt.2008.424","volume":"44","author":"T Daikeler","year":"2009","unstructured":"Daikeler, T. et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transpl. 44, 27\u201333 (2009).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR134","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41584-019-0306-7","volume":"15","author":"KM Sullivan","year":"2019","unstructured":"Sullivan, K. M. & Sarantopoulos, S. Allogeneic HSCT for autoimmune disease: a shared decision. Nat. Rev. Rheumatol. 15, 701\u2013702 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1050_CR135","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3389\/fneur.2020.556141","volume":"11","author":"F Roberts","year":"2020","unstructured":"Roberts, F. et al. Rehabilitation before and after autologous haematopoietic stem cell transplantation (AHSCT) for patients with multiple sclerosis (MS): consensus guidelines and recommendations for best clinical practice on behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). Front. Neurol. 11, 1602 (2020).","journal-title":"Front. Neurol."},{"key":"1050_CR136","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jnnp.68.4.450","volume":"68","author":"C Liu","year":"2000","unstructured":"Liu, C. & Blumhardt, L. D. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J. Neurol. Neurosurg. Psychiatry 68, 450\u2013457 (2000).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR137","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/135245859900500409","volume":"5","author":"J Fischer","year":"1999","unstructured":"Fischer, J., Rudick, R., Cutter, G. & Reingold, S. National MS Society Clinical Outcomes Assessment Task Force The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult. Scler. J. 5, 244\u2013250 (1999).","journal-title":"Mult. Scler. J."},{"key":"1050_CR138","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ane.12036","volume":"127","author":"R Motl","year":"2013","unstructured":"Motl, R. et al. Accelerometry as a measure of walking behavior in multiple sclerosis. Acta Neurol. Scand. 127, 384\u2013390 (2013).","journal-title":"Acta Neurol. Scand."},{"key":"1050_CR139","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L. et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 77, 1132\u20131140 (2020).","journal-title":"JAMA Neurol."},{"key":"1050_CR140","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1136\/jnnp-2013-307207","volume":"85","author":"J Burman","year":"2014","unstructured":"Burman, J. et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J. Neurol. Neurosurg. Psychiatry 85, 1116\u20131121 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1050_CR141","doi-asserted-by":"publisher","first-page":"103861","DOI":"10.1016\/j.msard.2022.103861","volume":"63","author":"GS Manzano","year":"2022","unstructured":"Manzano, G. S. et al. Disease modifying therapy management of multiple sclerosis after stem cell therapies: a retrospective case series. Mult. Scler. Relat. Disord. 63, 103861 (2022).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR142","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10072-017-2933-6","volume":"38","author":"B Casanova","year":"2017","unstructured":"Casanova, B. et al. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurol. Sci. 38, 1213\u20131221 (2017).","journal-title":"Neurol. Sci."},{"key":"1050_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2022.11.005","volume":"86","author":"P Miller","year":"2023","unstructured":"Miller, P. et al. Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: prepared on behalf of the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT), the Children\u2019s Cancer and Leukaemia Group (CCLG), and British Infection Association (BIA). J. Infect. 86, 1\u20138 (2023).","journal-title":"J. Infect."},{"key":"1050_CR144","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","volume":"19","author":"C Cordonnier","year":"2019","unstructured":"Cordonnier, C. et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 19, e200\u2013e212 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1050_CR145","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","volume":"24","author":"M van Aalst","year":"2018","unstructured":"van Aalst, M. et al. Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. Travel. Med. Infect. Dis. 24, 89\u2013100 (2018).","journal-title":"Travel. Med. Infect. Dis."},{"key":"1050_CR146","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas, A. et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 322, 123\u2013133 (2019).","journal-title":"JAMA"},{"key":"1050_CR147","doi-asserted-by":"publisher","first-page":"104102","DOI":"10.1016\/j.ebiom.2022.104102","volume":"81","author":"X Wu","year":"2022","unstructured":"Wu, X., Wang, L., Shen, L. & Tang, K. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine 81, 104102 (2022).","journal-title":"EBioMedicine"},{"key":"1050_CR148","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41409-021-01326-6","volume":"56","author":"R Greco","year":"2021","unstructured":"Greco, R. et al. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transpl. 56, 1493\u20131508 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR149","first-page":"33","volume":"56","author":"V Mehra","year":"2021","unstructured":"Mehra, V. et al. Early Morbidity of Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis-A Real World Experience. In: The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O010 \u2013 O169). Bone Marrow Transplantation 56, 33\u201334 (2021).","journal-title":"Bone Marrow Transplantation"},{"issue":"21","key":"1050_CR150","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1182\/blood.V116.21.4537.4537","volume":"116","author":"R Saccardi","year":"2010","unstructured":"Saccardi, R. et al. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation In autologous hematopoietic stem cell transplantation (HSCT) for severe multiple sclerosis (MS) [abstract]. Blood 116(21), 4537 (2010).","journal-title":"Blood"},{"key":"1050_CR151","first-page":"972","volume":"98","author":"JW Van Esser","year":"2001","unstructured":"Van Esser, J. W. et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT. Blood J. Am. Soc. Hematol. 98, 972\u2013978 (2001).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"1050_CR152","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 (2022).","journal-title":"Science"},{"key":"1050_CR153","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski, J. et al. Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 101, 803\u2013811 (2016).","journal-title":"Haematologica"},{"key":"1050_CR154","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/bmt.2011.185","volume":"47","author":"JA Snowden","year":"2012","unstructured":"Snowden, J. A. et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 47, 770\u2013790 (2012).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR155","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/cid\/ciz047","volume":"69","author":"V Mehra","year":"2019","unstructured":"Mehra, V. et al. Epstein-Barr virus and monoclonal gammopathy of clinical significance in autologous stem cell transplantation for multiple sclerosis. Clin. Infect. Dis. 69, 1757\u20131763 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1050_CR156","doi-asserted-by":"publisher","first-page":"757302","DOI":"10.3389\/fimmu.2021.757302","volume":"12","author":"U-C Meier","year":"2021","unstructured":"Meier, U.-C., Cipian, R. C., Karimi, A., Ramasamy, R. & Middeldorp, J. M. Cumulative roles for Epstein-Barr virus, human endogenous retroviruses, and human herpes virus-6 in driving an inflammatory cascade underlying MS pathogenesis. Front. Immunol. 12, 757302 (2021).","journal-title":"Front. Immunol."},{"key":"1050_CR157","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","volume":"88","author":"N Schwab","year":"2017","unstructured":"Schwab, N., Schneider-Hohendorf, T., Melzer, N., Cutter, G. & Wiendl, H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 88, 1197\u20131205 (2017).","journal-title":"Neurology"},{"key":"1050_CR158","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","volume":"12","author":"JR Berger","year":"2017","unstructured":"Berger, J. R. Classifying PML risk with disease modifying therapies. Mult. Scler. Relat. Disord. 12, 59\u201363 (2017).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1050_CR159","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458520952311","volume":"27","author":"L Moiola","year":"2021","unstructured":"Moiola, L. et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement. Mult. Scler. J. 27, 331\u2013346 (2021).","journal-title":"Mult. Scler. J."},{"key":"1050_CR160","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/10428194.2018.1474523","volume":"60","author":"D Adrianzen Herrera","year":"2019","unstructured":"Adrianzen Herrera, D. et al. Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant \u2013 a case series. Leuk. Lymphoma 60, 395\u2013401 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"1050_CR161","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1182\/blood-2011-02-336156","volume":"118","author":"T Daikeler","year":"2011","unstructured":"Daikeler, T. et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood 118, 1693\u20131698 (2011).","journal-title":"Blood"},{"key":"1050_CR162","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41409-021-01277-y","volume":"56","author":"RK Burt","year":"2021","unstructured":"Burt, R. K. et al. New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transpl. 56, 1509\u20131517 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"1050_CR163","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000868","volume":"7","author":"E Meltzer","year":"2020","unstructured":"Meltzer, E. et al. Mitigating alemtuzumab-associated autoimmunity in MS: a \u201cwhack-a-mole\u201d B-cell depletion strategy. Neurol. Neuroimmunol. Neuroinflamm. 7, e868 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1050_CR164","doi-asserted-by":"publisher","first-page":"20180390","DOI":"10.1259\/bjr.20180390","volume":"92","author":"C Demoor-Goldschmidt","year":"2019","unstructured":"Demoor-Goldschmidt, C. & de Vathaire, F. Review of risk factors of secondary cancers among cancer survivors. Br. J. Radiol. 92, 20180390 (2019).","journal-title":"Br. J. Radiol."},{"issue":"Suppl. 1","key":"1050_CR165","first-page":"25","volume":"57","author":"K Kirgizov","year":"2022","unstructured":"Kirgizov, K. et al. Late complications after autologous HSCT for autoimmune diseases: a retrospective study from the EBMT autoimmune diseases, transplant complications and paediatric diseases working parties [abstract O025]. Bone Marrow Transplant. 57 (Suppl. 1), 25\u201326 (2022).","journal-title":"Bone Marrow Transplant."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01050-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T13:02:56Z","timestamp":1741093376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01050-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":165,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-01050-x","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"11 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A.M. has received fees from consulting for Cellerys, Jasper Therapeutics and Magenta Therapeutics, all outside the submitted work. A.M. has received speaking honoraria from Biogen, Janssen, Novartis, Sanofi and Viatris, all outside the submitted work. R.G. has received speaker honoraria from Biotest, Magenta, Medac and Pfizer, all outside the submitted work. E.I. has received speaker fees and honoraria for advisory boards from Biogen, Merck and Sanofi-Genzyme, and an unrestricted research grant from Sanofi-Genzyme. M.I. is co-Editor of Multiple Sclerosis Journal and she has received honoraria for participating in educational activities or advisory boards for Biogen, Janssen, Merck, Novartis, Roche and Sanofi. T.A. has received honoraria and\/or travel grants from Amgen, AstraZeneca, GSK and Neovii, and study support from Amgen, Janssen-Cilag and Miltenyi. M.P.A. has served on scientific advisory boards for Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva; has received speaker honoraria from Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva; has received research grants for her Institution from Biogen, Merck, Novartis, Roche and Sanofi-Genzyme. She is co-Editor of Multiple Sclerosis Journal and Associate Editor of Frontiers in Neurology. G.B. was supported by a research fellowship FISM \u2013 Fondazione Italiana Sclerosi Multipla 019\/BR\/016, and financed or co-financed with the \u20185 per mille\u2019 public funding. O.C. has received personal compensation for consulting for Biogen, Merck and Novartis, and she serves as deputy Editor of Neurology. J.A.C. has received personal compensation for consulting for Astoria, Bristol-Myers Squibb, Convelo, EMD Serono, FiND Therapeutics, INMune, and Sandoz, and serves as an Editor of Multiple Sclerosis Journal. T.D. has received speaker fees, research support, travel support, and\/or served on advisory boards or steering committees of Alexion, Biogen, Celgene, GeNeuro, MedDay, Merck, Novartis, Roche and Sanofi-Genzyme; he has received research support from Swiss National Research Foundation, University of Basel, and the Swiss MS Society. M.G. has received educational support from Novartis and has an advisory board role for Merck. C.H. has received funding support, speaker honoraria and travel grants from Merck, Novartis and Roche. R.M. has received unrestricted grants from Biogen, Novartis, Roche and Third Rock; has advisory roles and has given lectures for Biogen, CellProtect, Genzyme, Neuway, Novartis, Roche, Swiss Rockets and Third Rock; is a patent holder and co-holder on patents for daclizumab in MS, JCV VP1 for vaccination against PML, JCV-specific neutralizing antibodies to treat PML, and antigen-specific tolerization with peptide-coupled cells and novel autoantigens in MS; is a co-founder of Abata, Cambridge, MA, USA (adoptive Treg therapy); and is a co-founder and employee of Cellerys. L.M. has received compensation for speaking activities and\/or consulting services from Alexion, Biogen, Celgene, Merck, Novartis, Roche and Sanofi. M.T. has received compensation for consulting services, speaking honoraria and research support from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Immunic Therapeutics, Janssen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Teva and Viela Bio; is on data safety monitoring boards for Parexel and UCB Biopharma; and is on the Relapse Adjudication Committee for Imcyse. B. Stankoff has received research support (to the institution) from Merck, Novartis and Roche, and personal speaker fees from Biogen, Janssen, Merck, Novartis and Sanofi. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}